Risk Capital Partners, the private equity firm chaired by Luke Johnson, today announces that it has bought a majority stake in Xstrahl, a medical devices business that designs and delivers effective clinical and research solutions to advance radiation oncology....
On January 29 - 30 the Nuclear Threat Initiative (NTI) together with the University of California and National Nuclear Security Administration (NNSA) held technical discussions on radiological risks associated with using cesium-137 irradiators for research and blood...
ASTRO Interview with Dr. Eric Ford A few months ago, I received the opportunity to sit down with notable physicist, professor, and experimental radiobiology researcher, Dr. Eric Ford. As one of the masterminds behind the Precision Proton Radiotherapy Platform, which...
Since October 2017, the radiation clinic and MVZ radiotherapy at the Sana Klinikum Offenbach have a new orthovolt device for X-ray irradiation. "We are pleased to be able to offer our patients another treatment option with the new device," explains chief physician...
January 31st, 2018 – Xstrahl, the leader in X-Ray Technology for treatment of Superficial Skin conditions is pleased to offer the new RADiant therapy system to Physician’s in America. Representing the next generation of compact radiotherapy systems, RADiant’s dual...
January 10th, 2018 – Xstrahl today released an upgrade to its Concerto software streamlining the clinical workflow for the entire range of the Xstrahl systems. Concerto 2.0 provides a streamlined workflow, enhanced connectivity options and a treatment verification...
January 4th, 2018 – The Xstrahl Group officially announced that Adrian Treverton has been promoted to Group CEO. This comes as the previous CEO, Martin Robinson retired in the new year after working for the company nearly 20 years. Adrian had more than 10 years of...
With skin cancer being the most common type of cancer in the USA the need for an effective and versatile treatment method is a necessity for many skin cancer centers. The Xstrahl 100 is perfectly suited for the treatment of superficial skin cancers, as used by the...
Xstrahl has received FDA clearance for the marketing of its latest skin cancer therapy device. RADiant System is a compact and ergonomic superficial X-Ray therapy system operating in the 10kV to 80kV range intended for superficial radiotherapy and surface electronic...
Contact Us